Reducing Risk of Cardiovascular Disease: Optimizing Lipid-Lowering Therapy in Primary and Secondary Prevention Patients is organized by University Learning Systems (ULS).

Course Expiration: 10/29/2022

Accreditation:
This online program in its entirety provides 5 hours (0.5 CEU) of ACPE CPE home study credit, AMA Category 2 CME, and CNE pharmacology credit. 

Course Objectives:
At the conclusion of this session, the participant will be able to:
• Review medications and lifestyle modifications that are recommended for the treatment of hypercholesterolemia.
• Identify the patient populations that benefit from statin therapy based on evidence from clinical trials.
• Apply the treatment approaches recommended in the 2018 ACC-AHA cholesterol guideline to patients with dyslipidemia.
• Define the role and optimal use of nonstatin therapy to lower LDL-C.
• Examine newer and emerging lipid-lowering by describing their mechanism of action, role in therapy, and efficacy in treating patients with dyslipidemia.
• Interpret results from large outcome studies evaluating lipid-lowering drug therapies, including omega-3 fatty acids and nonstatin medications used to lower LDL-C.
• Compare and contrast other cardiovascular drug treatments that are used to reduce risk of CV events in primary and secondary prevention patients.
• Examine the CV risk reduction benefits of medications used to treat type 2 diabetes.
• Create treatment plans for patients presenting with various lipid disorders.

Additional details will be posted as soon as information is available.